ProQR Therapeutics (PRQR) Market Cap to Net Income Ratio

Symbol and logo of brand ProQR Therapeutics (PRQR)

ProQR Therapeutics N.V. (PRQR) is a Dutch developer utilizing the Axiomer system for RNA modification, where advances from global pharma behemoths ensure capital stability. The price action, featuring the -3.70 metric, confirms the company's market position. Its model relies on the synthesis of genetics and targeted therapy to correct mutations. High scientific potential is realized through the preparation of clinical reports within the framework of global partnerships.

proqr.com (PRQR) - Price to Earnings Ratio from 07/04/2022 to 11/12/2026

Comprehensive metric breakdowns and analytics for ProQR (PRQR)

- market price and analyst price targets:
Market Price ProQR Therapeutics NV|PRQR - Price Target Chart
- market capitalization details:
Market Capitalization ProQR Therapeutics|PRQR - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share ProQR Therapeutics N.V.|PRQR - Company Net Assets|Market Value to Book Value proqr.com|PRQR - Cumulative Company Assets
- company liabilities and liquidity data:
Aggregate Debt to Capital ProQR Therapeutics N.V.|PRQR - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ProQR Therapeutics NV|PRQR - Company Aggregate Debts|Debts to Book Value ProQR Therapeutics|PRQR - Company Long-Term Debt|Company Short-Term Loans and Borrowings ProQR Therapeutics N.V.|Quick Ratio proqr.com
- earnings and valuation multiples indicators:
PRQR - Company Net Income|Forward Earnings ProQR Therapeutics N.V.|PRQR - P/E Multiple|Projected Price to Earnings Ratio ProQR Therapeutics NV|PRQR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ProQR Therapeutics|PRQR - Operating profit before deduction of amortization|Earnings per share for the last four quarters ProQR Therapeutics N.V.|PRQR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months proqr.com|PRQR - Earnings growth in current year|Expected earnings per share growth for next year ProQR Therapeutics N.V.
Summary company analysis:PRQR (proqr.com)
Finished products of ProQR Therapeutics N.V.

The P/E ratio determines the investment payback period via net income, reflecting market expectations regarding future earnings. Analyzing the base P/E of a company allows for an assessment of the asset's overvaluation relative to its current capitalization. This value is formed by the ratio of the market price per share to its annual earnings per share. For ProQR Therapeutics N.V. (PRQR), this indicator depends critically on the success of RNA therapy clinical trials and the stability of partner funding.

Analysis of competing companies

Market Cap to Earnings Tempus AI Inc TEM|Price to Earnings Ratio Qiagen (QGEN)|Ionis Pharmaceuticals, Inc. (IONS) - Market Cap to Net Income Ratio|Price to Earnings Ratio Repligen Corp. RGEN|Company Value to Net Income RNA|CRSP: Price to Earnings Ratio|Company Value to Net Income WGS (genedx.com)|RARE (Ultragenyx) - Price to Earnings Ratio|BEAM: Market Price to Net Income Ratio|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|TWST: Company Value to Net Income|P/E Multiple TXG|NTLA - Market Cap to Earnings|Price to Earnings Ratio Stoke Therapeutics, Inc. STOK|Company Value to Net Income BLFS|Wave Life Sciences Corp - P/E Multiple|MAZE - P/E Multiple|Sionna Therapeutics Inc (SION) - Price to Earnings Ratio|Market Cap to Net Income PRME (primemedicine.com)|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|Market Cap to Earnings uniQure NV QURE|Price to Earnings Ratio MGTX (MeiraGTx PLC)|P/E Multiple REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio OCGN (ocugen.com)|PacBio - P/E Multiple|Business Payback Period Benitec Biopharma Inc BNTC|DSGN: P/E Multiple|Price to Earnings Ratio Rocket Corp|Price to Earnings Ratio 4D Molecular Therapeutics|Lexeo (LXEO) - Business Payback Period|Price to Earnings Ratio KRRO (Korro Bio, Inc.)|EDIT (Editas Medicine Inc) - Company Value to Net Income|Price to Earnings Ratio Silence Therapeutics Inc. SLN|CDXS: Price to Earnings Multiple|SGMO: Price to Earnings Ratio|Business Payback Period Nautilus Biotechnology NAUT|MGX (Metagenomi) - Price to Earnings Ratio|DTIL (precisionbiosciences.com) - Price to Earnings Ratio|Price to Earnings Ratio GBIO|Boundless Bio Inc (BOLD) - Business Payback Period|Price to Earnings Ratio Exicure, Inc. (XCUR)|IMNN: Market Cap to Net Income|Price to Earnings Ratio Phio Pharmaceuticals Corp. PHIO|Company Value to Net Income MBIO|RNAZ - Price to Earnings Ratio|Market Cap to Net Income Ratio Bionano Genomics, Inc. (BNGO)|Applied DNA Sciences (APDN) - Price to Earnings Ratio|bluebirdbio.com - Company Value to Net Income|IPA (ImmunoPrecise Antibodies Ltd) - P/E Multiple|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|Price to Earnings Ratio Singular Genomics Systems Inc (OMIC)|Regulus - Price to Earnings Multiple|P/E Multiple SYRS (Syros Pharmaceuticals)|P/E Multiple telesisbio.com TBIO|TCON - Price to Earnings Ratio|Market Cap to Net Income UBX